- Home
- ACRS vs SRFM Comparison
ACRS vs SRFM Comparison
Compare ACRS & SRFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- SRFM
- Stock Information
- Founded
- ACRS 2012
- SRFM 2011
- Country
- ACRS United States
- SRFM United States
- Employees
- ACRS N/A
- SRFM N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- SRFM Transportation Services
- Sector
- ACRS Health Care
- SRFM Consumer Discretionary
- Exchange
- ACRS Nasdaq
- SRFM Nasdaq
- Market Cap
- ACRS 165.7M
- SRFM 185.9M
- IPO Year
- ACRS 2015
- SRFM 2023
- Fundamental
- Price
- ACRS $1.95
- SRFM $4.40
- Analyst Decision
- ACRS Strong Buy
- SRFM Buy
- Analyst Count
- ACRS 9
- SRFM 4
- Target Price
- ACRS $9.25
- SRFM $5.75
- AVG Volume (30 Days)
- ACRS 891.2K
- SRFM 1.8M
- Earning Date
- ACRS 11-05-2025
- SRFM 11-13-2025
- Dividend Yield
- ACRS N/A
- SRFM N/A
- EPS Growth
- ACRS N/A
- SRFM N/A
- EPS
- ACRS N/A
- SRFM N/A
- Revenue
- ACRS $16,789,000.00
- SRFM $107,372,000.00
- Revenue This Year
- ACRS N/A
- SRFM N/A
- Revenue Next Year
- ACRS N/A
- SRFM $18.06
- P/E Ratio
- ACRS N/A
- SRFM N/A
- Revenue Growth
- ACRS N/A
- SRFM N/A
- 52 Week Low
- ACRS $1.05
- SRFM $1.10
- 52 Week High
- ACRS $5.17
- SRFM $9.91
- Technical
- Relative Strength Index (RSI)
- ACRS 56.76
- SRFM 51.71
- Support Level
- ACRS $2.01
- SRFM $3.92
- Resistance Level
- ACRS $2.16
- SRFM $4.14
- Average True Range (ATR)
- ACRS 0.10
- SRFM 0.27
- MACD
- ACRS -0.01
- SRFM 0.00
- Stochastic Oscillator
- ACRS 47.44
- SRFM 50.85
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.